SG11202006873UA - Combination therapy for treating or preventing cancer - Google Patents

Combination therapy for treating or preventing cancer

Info

Publication number
SG11202006873UA
SG11202006873UA SG11202006873UA SG11202006873UA SG11202006873UA SG 11202006873U A SG11202006873U A SG 11202006873UA SG 11202006873U A SG11202006873U A SG 11202006873UA SG 11202006873U A SG11202006873U A SG 11202006873UA SG 11202006873U A SG11202006873U A SG 11202006873UA
Authority
SG
Singapore
Prior art keywords
treating
combination therapy
preventing cancer
cancer
preventing
Prior art date
Application number
SG11202006873UA
Inventor
Alexander Stevenson
Original Assignee
4D Pharma Res Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB1800927.4A external-priority patent/GB201800927D0/en
Priority claimed from GBGB1801502.4A external-priority patent/GB201801502D0/en
Priority claimed from GBGB1805941.0A external-priority patent/GB201805941D0/en
Priority claimed from GBGB1806572.2A external-priority patent/GB201806572D0/en
Priority claimed from GBGB1808631.4A external-priority patent/GB201808631D0/en
Application filed by 4D Pharma Res Ltd filed Critical 4D Pharma Res Ltd
Publication of SG11202006873UA publication Critical patent/SG11202006873UA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3076—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties
    • C07K16/3084—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties against tumour-associated gangliosides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
SG11202006873UA 2018-01-19 2019-01-18 Combination therapy for treating or preventing cancer SG11202006873UA (en)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
GBGB1800927.4A GB201800927D0 (en) 2018-01-19 2018-01-19 Combination therapy for treating or preventing cancer
GBGB1801502.4A GB201801502D0 (en) 2018-01-30 2018-01-30 Combination therapy for treating or preventing cancer
GBGB1805941.0A GB201805941D0 (en) 2018-04-10 2018-04-10 Combination therapy for treating or preventing cancer
GBGB1806572.2A GB201806572D0 (en) 2018-04-23 2018-04-23 Combination therapy for treating or preventing cancer
GBGB1808631.4A GB201808631D0 (en) 2018-05-25 2018-05-25 Combination therapy for treating or preventing cancer
PCT/GB2019/050143 WO2019141998A1 (en) 2018-01-19 2019-01-18 Combination therapy for treating or preventing cancer

Publications (1)

Publication Number Publication Date
SG11202006873UA true SG11202006873UA (en) 2020-08-28

Family

ID=65278398

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202006873UA SG11202006873UA (en) 2018-01-19 2019-01-18 Combination therapy for treating or preventing cancer

Country Status (14)

Country Link
US (2) US20210060086A1 (en)
EP (1) EP3740220A1 (en)
JP (1) JP2021516662A (en)
KR (1) KR20200110342A (en)
CN (1) CN111727047A (en)
AU (1) AU2019210004A1 (en)
BR (1) BR112020014565A2 (en)
CA (1) CA3088338A1 (en)
IL (1) IL276074A (en)
MA (1) MA51615A (en)
MX (1) MX2020007664A (en)
SG (1) SG11202006873UA (en)
TW (1) TW201934139A (en)
WO (1) WO2019141998A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023072968A1 (en) * 2021-10-25 2023-05-04 4D Pharma Research Ltd Compositions comprising bacterial strains

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0127916D0 (en) 2001-11-21 2002-01-16 Rowett Res Inst Method
US20100168410A1 (en) 2006-10-27 2010-07-01 Pfizer Products Inc. Hydroxypropyl Methyl Cellulose Hard Capsules and Process of Manufacture
GB201112091D0 (en) 2011-07-14 2011-08-31 Gt Biolog Ltd Bacterial strains isolated from pigs
GB201117313D0 (en) 2011-10-07 2011-11-16 Gt Biolog Ltd Bacterium for use in medicine
GB201306536D0 (en) 2013-04-10 2013-05-22 Gt Biolog Ltd Polypeptide and immune modulation
RU2017141448A (en) * 2015-06-01 2019-07-15 Зэ Юниверсити Оф Чикаго TREATMENT OF CANCER BY MANIPULATION WITH COMMENSAL MICROFLORA
GB201520497D0 (en) * 2015-11-20 2016-01-06 4D Pharma Res Ltd Compositions comprising bacterial strains
SG11201804161VA (en) * 2015-11-20 2018-06-28 4D Pharma Res Ltd Compositions comprising bacterial strains
TW201907931A (en) * 2017-05-24 2019-03-01 英商4D製藥研究有限公司 Composition comprising a bacterial strain

Also Published As

Publication number Publication date
US20210060086A1 (en) 2021-03-04
BR112020014565A2 (en) 2020-12-08
IL276074A (en) 2020-08-31
MA51615A (en) 2020-11-25
WO2019141998A1 (en) 2019-07-25
JP2021516662A (en) 2021-07-08
TW201934139A (en) 2019-09-01
CN111727047A (en) 2020-09-29
MX2020007664A (en) 2020-09-14
CA3088338A1 (en) 2019-07-25
EP3740220A1 (en) 2020-11-25
US20230277602A1 (en) 2023-09-07
AU2019210004A1 (en) 2020-08-13
KR20200110342A (en) 2020-09-23

Similar Documents

Publication Publication Date Title
IL290149A (en) Combination therapy for cancer treatment
IL267795A (en) Combination therapy for the treatment of cancer
EP3407978A4 (en) Combination therapy for treating cancer
EP3678663A4 (en) Combination therapy for treating cancer
IL274837B1 (en) Combination therapy for the treatment of cancer
IL275949A (en) Combination therapy for treating or preventing cancer
GB201903546D0 (en) Cancer treatment
IL281845A (en) Combination therapy for the treatment of cancer
IL282093A (en) Combination therapy for cancer
IL281439A (en) Combination therapy for treating blood cancer
IL284162A (en) Combination therapy for the treatment of cancer
SG11202010528XA (en) Combinations for treating cancer
IL287652A (en) Cancer treatment
IL266993A (en) Combination therapy for the treatment of cancer
IL285466A (en) Cancer treatment
IL281281A (en) Combination therapy for the treatment of prostate cancer
IL276074A (en) Combination therapy for treating or preventing cancer
IL276073A (en) Combination therapy for treating or preventing cancer
IL275860A (en) Combination therapy for treating or preventing cancer
IL288178A (en) Gmci and ddri combination therapy for treating cancer
IL286680A (en) Medicament for treating cancer
IL288035A (en) Cancer treatment
IL278921A (en) Combination therapies for treating cancer
GB201819920D0 (en) Cancer treatment
IL253642A0 (en) Combination therapy for the treatment of cancer